Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice
- PMID: 10496944
- PMCID: PMC96919
- DOI: 10.1128/IAI.67.10.5526-5529.1999
Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice
Abstract
Seroepidemiological data and a clinical trial with a Shigella sonnei O-specific polysaccharide (O-SP)-Pseudomonas aeruginosa recombinant exoprotein A (rEPA) conjugate provide evidence that a critical level of immunoglobulin G (IgG) lipopolysaccharide (LPS) antibodies in serum confers protection against shigellosis. We evaluated the immunogenicity of conjugates whose carrier proteins and O-SPs were treated with succinic anhydride (SA), which reacts with amino groups at neutral pH to form amide-linked carboxyls (succinylation). Conjugates were synthesized with either of two genetically inactivated medically useful toxins, the diphtheria protein CRM9 or rEPA, bound to the O-SP of Shigella flexneri type 2a. Conjugates composed of the succinylated protein, succinylated O-SP, or both succinylated components were administered to mice by a clinically relevant scheme, and their levels of serum IgG anti-LPS and anti-proteins were assayed 7 days after the second and third injections. CRM9 served as a more immunogenic carrier than rEPA. Conjugates composed of succinylated components were more immunogenic than the conjugates composed of the native components. SA treatment of both the carrier protein and the O-SP did not confer an advantage over the succinylated protein alone. Conjugates prepared with native proteins, in general, elicited slightly higher levels of IgG protein antibodies than conjugates composed of the SA-treated proteins.
Figures
Similar articles
-
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene.Vaccines (Basel). 2022 Apr 24;10(5):675. doi: 10.3390/vaccines10050675. Vaccines (Basel). 2022. PMID: 35632431 Free PMC article. Review.
-
Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel.Infect Immun. 2001 Mar;69(3):1351-7. doi: 10.1128/IAI.69.3.1351-1357.2001. Infect Immun. 2001. PMID: 11179298 Free PMC article. Clinical Trial.
-
Safety and immunogenicity of Shigella sonnei-CRM9 and Shigella flexneri type 2a-rEPAsucc conjugate vaccines in one- to four-year-old children.Pediatr Infect Dis J. 2003 Aug;22(8):701-6. doi: 10.1097/01.inf.0000078156.03697.a5. Pediatr Infect Dis J. 2003. PMID: 12913770 Clinical Trial.
-
Quantitative analysis of IgG class and subclass and IgA serum response to Shigella sonnei and Shigella flexneri 2a polysaccharides following vaccination with Shigella conjugate vaccines.Vaccine. 1999 Aug 6;17(23-24):3109-15. doi: 10.1016/s0264-410x(99)00136-x. Vaccine. 1999. PMID: 10462247 Clinical Trial.
-
Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides.Clin Infect Dis. 1992 Aug;15(2):346-61. doi: 10.1093/clinids/15.2.346. Clin Infect Dis. 1992. PMID: 1381621 Review.
Cited by
-
Exploring the variables influencing the immune response of traditional and innovative glycoconjugate vaccines.Front Mol Biosci. 2023 May 16;10:1201693. doi: 10.3389/fmolb.2023.1201693. eCollection 2023. Front Mol Biosci. 2023. PMID: 37261327 Free PMC article. Review.
-
Detoxified O-Specific Polysaccharide (O-SP)-Protein Conjugates: Emerging Approach in the Shigella Vaccine Development Scene.Vaccines (Basel). 2022 Apr 24;10(5):675. doi: 10.3390/vaccines10050675. Vaccines (Basel). 2022. PMID: 35632431 Free PMC article. Review.
-
Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human.Hum Vaccin Immunother. 2019;15(6):1338-1356. doi: 10.1080/21645515.2019.1606972. Hum Vaccin Immunother. 2019. PMID: 31158047 Free PMC article. Review.
-
Vaccines against gastroenteritis, current progress and challenges.Gut Microbes. 2020 Nov 1;11(6):1486-1517. doi: 10.1080/19490976.2020.1770666. Epub 2020 Jun 18. Gut Microbes. 2020. PMID: 32552414 Free PMC article. Review.
-
Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Infect Immun. 2002 Nov;70(11):5982-9. doi: 10.1128/IAI.70.11.5982-5989.2002. Infect Immun. 2002. PMID: 12379673 Free PMC article.
References
-
- Anderson P W, Pichichero M E, Stein E C, Porcelli S, Betts R F, Connuck D M, Korones D, Insel R A, Zahradnik J M, Eby R. Effect of oligosaccharide chain length, exposed terminal group, and hapten loading on the antibody response of human adults and infants to vaccines consisting of Haemophilus influenzae type b capsular antigen uniterminally coupled to the diphtheria protein CRM197. J Immunol. 1989;142:2464–2468. - PubMed
-
- Ashkenazi S, Passwell J H, Harlev E, Miron D, Dagan R, Farzan N, Ramon R, Majadly F, Bryla D A, Karpas A B, Robbins J B, Schneerson R the Israel Pediatric Shigella Study Group. Safety and immunogenicity of Shigella sonnei and Shigella flexneri 2a O-specific polysaccharide conjugates in children. J Infect Dis. 1999;179:1565–1568. - PubMed
-
- Black R E, Brown K H, Becker S. Effects of diarrhea associated with specific enteropathogens on the growth of children in rural Bangladesh. Pediatrics. 1984;73:799–805. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources